How to Get Rezdiffra (Resmetirom) in Washington

What Is Rezdiffra and Who Qualifies in Washington?

Rezdiffra (resmetirom) is the first FDA-approved medication specifically targeting metabolic dysfunction-associated steatohepatitis (MASH), formerly called non-alcoholic steatohepatitis (NASH). The FDA granted accelerated approval in March 2024 for adults with non-cirrhotic MASH and moderate-to-advanced hepatic fibrosis, classified as stages F2 or F3 on the METAVIR scale [1].

How Resmetirom Works

Resmetirom is a selective thyroid hormone receptor-beta (THR-β) agonist. It activates THR-β in the liver to reduce hepatic fat, lower atherogenic lipoproteins, and decrease markers of liver inflammation. Unlike systemic thyroid hormones, resmetirom does not significantly stimulate THR-α, which means it spares the heart and bone from classic hyperthyroid effects [2]. In the MAESTRO-NASH trial (N=966), 80 mg and 100 mg doses of resmetirom achieved MASH resolution without worsening fibrosis in 25.9% and 29.9% of patients respectively at 52 weeks, compared to 9.7% with placebo (P<0.001 for both doses) [1].

Eligibility Criteria

Washington prescribers typically confirm eligibility using these criteria:

• Diagnosed MASH (via biopsy or validated non-invasive testing)
• Fibrosis stage F2 or F3 (non-cirrhotic)
• Age 18 or older
• No decompensated cirrhosis (Child-Pugh B or C)

Patients with F0-F1 fibrosis or compensated cirrhosis (F4) fall outside the current approved indication. The Endocrine Society and American Association for the Study of Liver Diseases (AASLD) both note that prescribing should be limited to the population studied in MAESTRO-NASH until confirmatory trial data are available [3].

Step-by-Step: Getting a Rezdiffra Prescription in Washington

The path from initial evaluation to filling your first prescription typically spans 2 to 6 weeks, depending on insurance type and how quickly labs and prior authorization are completed. Here is the standard sequence Washington patients follow.

Step 1: Clinical Evaluation and Diagnosis

Schedule an appointment with a hepatologist, gastroenterologist, or an experienced primary care provider. Your clinician needs to confirm a MASH diagnosis with fibrosis staging. Acceptable methods include liver biopsy (the reference standard), vibration-controlled transient elastography (FibroScan with a result between 8.0 and 13.9 kPa for F2-F3), or a validated serum panel such as FIB-4 or the Enhanced Liver Fibrosis (ELF) test [4].

Step 2: Baseline Labs

Before initiating resmetirom, the FDA-approved prescribing information requires thyroid function tests (TSH, free T4), a comprehensive metabolic panel including ALT and AST, and a pregnancy test for individuals of childbearing potential. Lipid panels are also standard because resmetirom significantly reduces LDL-C and triglycerides [1].

Step 3: Prior Authorization (If Insured)

Most commercial plans and Washington Medicaid require prior authorization (PA). PA documentation typically includes:

• Confirmed MASH diagnosis with the method of diagnosis
• Fibrosis staging results (F2 or F3)
• Baseline liver function labs
• Attestation that the patient does not have decompensated cirrhosis
• Trial or intolerance documentation for lifestyle modifications

Washington Medicaid specifically covers Rezdiffra with PA for the MASH indication. PA turnaround ranges from 3 to 14 business days depending on the payer.

Step 4: Prescription and Pharmacy

Once PA is approved, the prescriber sends the prescription to a specialty pharmacy. Rezdiffra is dispensed as a 60 mg or 100 mg oral tablet taken once daily. Many patients start at 80 mg (administered as a 60 mg tablet in the morning) for the first 60 days, then increase to 100 mg based on tolerability [1].

Telehealth Access to Rezdiffra in Washington

Washington state permits telehealth prescribing for Rezdiffra, which makes the medication accessible to patients in rural and underserved areas across the state. A licensed prescriber (MD, DO, NP, or PA) with an active Washington credential can evaluate, diagnose, and prescribe resmetirom via a synchronous audio-video visit.

What Telehealth Providers Need From You

Telehealth visits for Rezdiffra require the same clinical documentation as in-person appointments. You will need to upload or share recent imaging (FibroScan report or biopsy pathology), lab results (LFTs, lipid panel, TSH), and a current medication list before the visit. Some telehealth platforms partner directly with specialty pharmacies, which can shorten the time between prescription and delivery.

Washington Telehealth Regulations

Under Washington's Telehealth Parity Act (RCW 48.43.735), commercial insurers must cover telehealth-delivered services at the same rate as in-person visits. This applies to the clinical evaluation that leads to a Rezdiffra prescription. Washington Medicaid (Apple Health) also reimburses telehealth encounters for hepatology and gastroenterology consultations. Patients in counties without a local hepatologist, such as parts of Eastern Washington, Okanogan County, or the Olympic Peninsula, benefit most from this pathway.

Choosing a Qualified Telehealth Provider

Look for providers with documented experience managing MASH or chronic liver disease. Board certification in hepatology or gastroenterology is the strongest signal of clinical competence, though experienced internists and family medicine providers with MASH-specific training also prescribe resmetirom. Ask whether the provider handles the prior authorization process directly or if you will need to manage it separately.

Pharmacy Options in Washington

Rezdiffra is classified as a specialty medication, so not every retail pharmacy stocks it. Washington patients have three main dispensing channels.

Specialty Retail Pharmacies

National specialty pharmacy chains with Washington locations (including Accredo, CVS Specialty, and Optum Specialty) carry Rezdiffra. Your insurer may require you to use a preferred specialty pharmacy within their network. These pharmacies typically ship directly to your home with cold-chain packaging if required.

503A Compounding Pharmacies

Licensed 503A compounding pharmacies in Washington can compound resmetirom for individual patient prescriptions. This route is most relevant for patients who need a non-standard dose form or who face barriers with the branded product. Under Washington State Pharmacy Quality Assurance Commission rules, 503A pharmacies must compound pursuant to a valid patient-specific prescription from a licensed prescriber [5].

Mail-Order and Specialty Delivery

Most specialty pharmacies ship Rezdiffra statewide within 1 to 3 business days after PA approval and order processing. Patients in remote areas of Washington (Ferry County, San Juan Islands, etc.) may experience an additional day of transit. Signature confirmation is standard for specialty medication deliveries.

Insurance Coverage and Cost in Washington

Rezdiffra carries a wholesale acquisition cost of approximately $47,400 per year. Out-of-pocket cost varies widely depending on your insurance type.

Commercial Insurance

Most large commercial insurers in Washington (Premera Blue Cross, Regence BlueShield, Molina, Kaiser Permanente of Washington) have begun adding Rezdiffra to their formularies with prior authorization and step therapy requirements. Typical commercial copays after PA range from $25 to $150 per month when copay assistance is applied.

Madrigal Copay Assistance Program

Madrigal Pharmaceuticals offers a copay assistance program for commercially insured patients that can reduce out-of-pocket costs to as low as $0 per month for eligible individuals. Patients with government insurance (Medicare, Medicaid, Tricare) are not eligible for manufacturer copay cards per federal anti-kickback regulations. Check Madrigal's patient support page for current program terms.

Washington Medicaid (Apple Health)

Washington Medicaid covers Rezdiffra with prior authorization for the approved MASH indication. The PA process through Apple Health requires documentation of fibrosis stage, diagnosis method, and baseline labs. Medicaid patients typically pay $0 to $3 per prescription fill depending on their plan tier.

Medicare

Medicare Part D plans may cover Rezdiffra, though formulary placement varies by plan. Patients enrolled in Medicare Advantage plans through Washington-based insurers should verify coverage through their plan's specialty pharmacy team. The Inflation Reduction Act's $2,000 annual Part D out-of-pocket cap (effective 2025) may apply to Rezdiffra costs for Medicare beneficiaries [6].

Labs and Monitoring After Starting Rezdiffra

Ongoing monitoring is required while taking resmetirom. The prescribing label and clinical practice both call for specific lab surveillance.

First 12 Months

• Thyroid function (TSH, free T4): Check at baseline, 4 weeks, 8 weeks, and every 6 months thereafter. Resmetirom can suppress TSH modestly without causing clinical hyperthyroidism, but monitoring catches the rare patient who develops thyroid axis disruption [2].
• Liver enzymes (ALT, AST): Check at baseline, 4 weeks, 12 weeks, and every 3 months in the first year. In MAESTRO-NASH, ALT reductions of 36% were observed at 24 weeks with the 100 mg dose [1].
• Lipid panel: Check at baseline and 12 weeks. Resmetirom reduced LDL-C by 13.6% and triglycerides by 22.4% at 52 weeks in MAESTRO-NASH [1].

Long-Term Monitoring

After the first year, most clinicians shift to every-6-month lab checks for thyroid function and liver enzymes, with annual FibroScan or non-invasive fibrosis reassessment. The confirmatory phase of the MAESTRO-NASH trial is ongoing, and long-term fibrosis regression data will inform whether monitoring intervals can be extended.

Who Can Prescribe Rezdiffra in Washington?

Washington state does not restrict Rezdiffra prescribing to a specific specialty. Any provider with prescriptive authority and a valid DEA registration (resmetirom is not a controlled substance, so a standard NPI suffices) can write the prescription.

Prescriber Hierarchy

• MDs and DOs: Gastroenterologists and hepatologists are the most common prescribers. Internal medicine physicians and endocrinologists with MASH experience also prescribe.
• Nurse Practitioners (ARNPs): Washington grants full practice authority to ARNPs, meaning NPs can independently evaluate, diagnose, and prescribe Rezdiffra without physician supervision [7].
• Physician Assistants (PAs): PAs in Washington practice under a collaborative agreement but can prescribe legend drugs including resmetirom.

The practical bottleneck is not licensure but clinical competence. Insurers may deny PA requests from prescribers who lack documented liver disease management experience, so patients benefit from seeing a provider whose practice regularly manages MASH.

Prior Authorization: What Washington Payers Require

PA is the most common barrier to timely access. While each payer has its own criteria, the typical Washington PA package includes the following.

Required Documentation

1. ICD-10 code K75.81 (non-alcoholic steatohepatitis)
2. Fibrosis staging result with method (biopsy pathology report, FibroScan kPa value, or FIB-4/ELF score)
3. Baseline labs: ALT, AST, TSH, free T4, CBC, comprehensive metabolic panel
4. Confirmation that fibrosis is F2 or F3 (not F0-F1 or F4)
5. Statement that patient has tried or is concurrently using lifestyle modifications (diet, exercise, weight management)
6. Prescriber attestation that patient does not have decompensated cirrhosis

Turnaround and Appeals

Standard PA decisions in Washington are required within 5 business days for non-urgent requests under WAC 284-43-2050. Expedited (urgent) requests must be decided within 72 hours. If denied, patients have the right to an internal appeal followed by an external review through the Washington Office of the Insurance Commissioner. Denial rates for Rezdiffra PA are highest when fibrosis staging documentation is incomplete or when the prescriber submits without specifying the diagnostic method.

MAESTRO-NASH Trial: The Evidence Behind Rezdiffra

Rezdiffra's approval rests primarily on the MAESTRO-NASH phase 3 trial, published in the New England Journal of Medicine in February 2024. This is the largest completed randomized controlled trial in MASH drug development.

Key Results

The trial enrolled 966 adults with biopsy-confirmed MASH and fibrosis stages F1B through F3 across 198 sites. At 52 weeks, the co-primary endpoints showed:

• MASH resolution without fibrosis worsening: 25.9% (80 mg) and 29.9% (100 mg) vs. 9.7% placebo [1]
• Fibrosis improvement by at least one stage without NASH worsening: 24.2% (80 mg) and 25.9% (100 mg) vs. 14.2% placebo [1]

Both doses met both co-primary endpoints with statistical significance. The trial also demonstrated a favorable metabolic profile: LDL-C, triglycerides, and liver fat (measured by MRI-PDFF) all decreased significantly compared to placebo.

Safety Profile

The most common adverse events in MAESTRO-NASH were diarrhea (27% vs. 18% placebo) and nausea (22% vs. 13% placebo), predominantly mild to moderate and concentrated in the first 4 to 8 weeks. Serious adverse event rates were similar across treatment and placebo groups. No cases of clinically significant thyrotoxicosis were reported [1].

Dr. Stephen Harrison, principal investigator of MAESTRO-NASH, stated: "Resmetirom is the first drug to demonstrate both NASH resolution and fibrosis improvement in a phase 3 trial, which is a meaningful clinical milestone for patients who previously had no FDA-approved pharmacologic option" [1].

The AASLD's 2024 practice guidance notes: "Resmetirom may be considered for adults with non-cirrhotic MASH and stage F2 or F3 fibrosis who are appropriate candidates for pharmacotherapy, pending confirmatory outcomes data" [3].

Timeline: How Long Until You Receive Rezdiffra in Washington?

The total timeline from first appointment to medication in hand breaks down as follows for most Washington patients.

| Step | Typical Duration | |---|---| | Initial evaluation and labs | 1 to 2 weeks | | FibroScan or biopsy (if not already done) | 1 to 3 weeks | | Prior authorization submission and approval | 3 to 14 business days | | Specialty pharmacy processing and shipping | 1 to 3 business days | | Total estimate | 2 to 6 weeks |

Patients who already have recent fibrosis staging and labs from a prior hepatology visit can compress this timeline to as little as 10 days. Telehealth evaluations can eliminate scheduling delays associated with specialist wait times in Washington, which average 28 days for gastroenterology according to the Merritt Hawkins 2024 physician wait time survey [8].